Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Intravenous MR11A8 in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome

Next Previous
X
Search
Trial Profile

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Intravenous MR11A8 in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Maruishi Pharmaceutical

    • Most Recent Events

    • 02 Mar 2020 According to a Faron Pharmaceuticals media release,Status changed to completed.
    • 27 Jun 2018 Planned End Date changed from 31 Dec 2018 to 31 Mar 2019.
    • 11 Dec 2017 According to a Faron Pharmaceuticals media release, Faron's Japanese partner Maruishi expects results of this trial in 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top